行情

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

实时行情|Nasdaq Last Sale

0.1330
-0.0058
-4.18%
盘前: 0.1130 -0.02 -15.04% 08:00 11/20 EST
开盘
0.1345
昨收
0.1388
最高
0.1463
最低
0.1300
成交量
172.92万
成交额
--
52周最高
0.5250
52周最低
0.1201
市值
341.21万
市盈率(TTM)
-0.2112
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PHIO 新闻

  • 拼多多Q3净亏损超预期 盘前跌逾20%市值回落百度之后
  • 新浪财经.2小时前
  • 拼多多三季度营收低于市场预期 盘前大跌13%
  • 新浪科技.2小时前
  • 定价176港元,阿里巴巴首日盈利空间还有多大?
  • 华盛通.2小时前
  • 阿里巴巴融资880亿港元 为2010年以来香港最大IPO
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
+1.99%
制药与医学研究
+0.74%

热门股票

名称
价格
涨跌幅

PHIO 简况

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
展开

Webull提供Phio Pharmaceuticals Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。